Heat-Inactivated Complement Factor B for Thrombotic Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for thrombotic microangiopathies and complement-mediated inflammatory disorders, such as atypical hemolytic-uremic syndrome, are limited by excessive activation of the alternative complement pathway, leading to renal failure and other organ dysfunctions, with unclear initiation mechanisms and inadequate therapeutic options.
Innovation Solution
A composition comprising heat-inactivated complement factor B is administered to inhibit the alternative complement pathway activation, using heat-inactivated complement factor B derived from plasma or purified from human sources, which binds to C3b and prevents further activation, thereby reducing C3b and C5 convertase formation on endothelial cell-secreted von Willebrand factor strings.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If heat-inactivated complement factor B is administered to inhibit alternative complement pathway activation, then complement-mediated tissue damage is reduced, but the complexity of the therapeutic composition increases
Solution Approach 1:
The patent extracts and isolates the harmful factor (complement factor B) from the complete complement system, creating a targeted therapeutic composition that specifically addresses alternative pathway activation without requiring modification of the entire complement system. This extraction approach allows selective inhibition of pathogenic processes while maintaining overall system functionality.
Solution Approach 2:
The patent applies heat inactivation (temperature parameter change) to complement factor B to selectively alter its functional properties. By heating the factor B preparation to specific temperatures, the therapeutic composition achieves inactivation of the factor B's complement-activating capability while preserving its structural integrity for targeted therapeutic action.
2Reliability
If heat-inactivated complement factor B binds to C3b to prevent convertase formation, then excessive complement activation is reduced, but the specificity of the therapeutic mechanism becomes more complex
Solution Approach 1:
The patent employs heat-inactivated complement factor B as an intermediary substance that mediates the inhibition of alternative pathway amplification. The inactivated factor B acts as a decoy or blocking agent that interferes with the normal interaction between C3b and active factor B, thereby preventing convertase formation without directly activating or inhibiting other complement components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of heat-inactivated complement factor B effectively reduces alternative complement pathway activation, decreasing C3b and C5 convertase formation, thereby mitigating thrombotic microangiopathies and complement-mediated inflammatory disorders by inhibiting excessive complement activation and preventing renal damage.
Implementation Method 1
heat-inactivated complement factor B
Data Source
AI summary
The present disclosure is directed to compositions comprising heat-inactivated complement factor B and methods of using the same to treat thrombotic or complement-mediated inflammatory disorders.